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Abstract 
Background In preparation for the introduction of MenAfriVac®, a meningococcal group A conjugate 
vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was 
established. We analysed surveillance data on suspected and confirmed cases of meningitis to 
quantify vaccine impact. 
Methods Surveillance data from - (Benin, Burkina Faso, Chad, Côte d’Ivoire, Ghana, Mali, Niger, 
Nigeria, Togo)collected and curated by the World Health Organisation Inter-country Support Team 
between 2005-2015 were included. The incidence rate ratios of suspected and confirmed cases in 
vaccinated and unvaccinated populations were estimated using  negative binomial regression 
models. The relative risk of districts reaching the epidemic threshold of 10 per 100,000 per week was 
estimated according to district vaccination status. 
Findings The incidence of suspected meningitis cases declined by 57% (95%CI 55-59%) in vaccinated 
compared to unvaccinated populations, with some heterogeneity observed by country. We observed 
a similar 59% decline in the risk of a district reaching the epidemic threshold. In fully vaccinated 
populations the incidence of confirmed group A disease was reduced by >99%. The incidence rate 
ratio for non-A serogroups was higher after completion of MenAfriVac® campaigns (IRR 2.76, 95% CI 
1.21, 6.30).  
Interpretation MenAfriVac® introduction has led to considerable reductions in the incidence of 
suspected meningitis and epidemic risk and a dramatic impact on confirmed group A meningococcal 
meningitis. It is important to continue strengthening surveillance to monitor vaccine performance 
and remain vigilant against threats from other meningococcal serogroups and other pathogens. 
Funding The study was supported by the World Health Organisation.  
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Introduction 
Countries in the “African meningitis belt”, an area in sub-Saharan Africa that stretches from Senegal 
in the west to Ethiopia in the east, are susceptible to devastating outbreaks of meningococcal 
meningitis, with population attack rates as high as 1% during major epidemics1.  Most epidemics in 
the past have been due to group A Neisseria meningitidis (NmA), but epidemics due to other 
serogroups (NmC, NmW, NmX) have been recorded2-4. An enhanced meningitis surveillance network 
was established across the meningitis belt in 20035. Each country reports to the WHO Intercountry 
Support Team (IST) for West Africa, the data is stored in a central database, and a surveillance 
bulletin is disseminated each week in the meningitis season (weeks 1-26) and monthly the rest of 
the year.  
The phased introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac®) 
through mass vaccination campaigns targeting 1-29 year olds into the 26 countries of the African 
meningitis belt started in 2010, with the aim of completing the campaigns in 20176. Countries are 
now planning for the introduction of MenAfriVac into the routine Expanded Programme on 
Immunization (EPI) schedule between the ages of 9 and 18 months7. This vaccine offers the hope of 
eliminating group A epidemics as a public health problem in Africa8. A report on meningitis incidence 
trends in the meningitis belt from 2004 until 2013 was recently published5, but this analysis  did not 
take account of the year of introduction of MenAfriVac® . We present a model of vaccine impact on 
the incidence of suspected and confirmed cases of meningitis in nine countries of the meningitis 
belt. This analysis takes account of the timing of vaccine introduction and extends the period of 
evaluation through 2015.  
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Methods 
Definitions 
Suspected meningitis case. Any person with sudden onset of fever (>38.5°C rectal or 38.0°C axillary) 
and one of the following signs: neck stiffness, flaccid neck (infants), bulging fontanelle (infants), 
convulsion or other meningeal signs9.  
Confirmed meningitis case. Any person with meningeal signs and isolation of a causal pathogen (N. 
meningitidis (Nm), Streptococcus pneumoniae (Spn), Haemophilus influenzae type b (Hib)) from the 
cerebrospinal fluid (CSF) by culture, polymerase chain reaction or rapid diagnostic test9. 
Data sources 
An enhanced meningitis surveillance network was established across the meningitis belt in 20035. 
Standard Operating Procedures, including standard case definitions (see above), intervention 
thresholds, laboratory standards and data collection tools were developed for surveillance officers, 
enabling them to use the same methods to detect and notify cases10. We included nine countries in 
the meningitis belt that introduced MenAfriVac® before 2014 and consistently submitted weekly 
district level surveillance reports of suspected meningitis cases to IST.  We used data from Benin, 
Burkina Faso, Côte d’Ivoire, Ghana, Mali, Niger, and Togo from 2005 to 2015, data from Chad from 
2006 onwards and data from Nigeria from 2007 onwards are also included. District level population 
estimates were submitted by each country in their surveillance reports. National level population 
was calculated as the sum of the district populations submitted to the WHO-IST.  
In each year, the proportion of suspected cases that were confirmed was generally low. Given the 
paucity of confirmed cases at a weekly district level, we used data on confirmed cases at an annual 
country level, taken from the WHO bulletins at week 52 of each year for 2005 to 2015. The data on 
confirmed cases are not individually linked to the suspected case data..  
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For each country, details of the timing and targeted populations (if not a national campaign) for 
MenAfriVac® introduction were obtained from Meningitis Vaccine Project and WHO sources 
(summarised in Table S1).  Vaccination on a district level was considered to be complete the week 
after the reported campaign ended. For laboratory confirmed cases, where data were only available 
annually at national level, the country-level vaccination status was categorised as unvaccinated 
(before the start of campaigns), partially vaccinated if campaigns were phased over more than one 
year or fully vaccinated the year following the completion of mass campaigns. We considered the 
time of vaccination relative to the meningitis season, e.g. Burkina Faso was considered unvaccinated 
in 2010 as the MenAfriVac® campaigns were conducted in December 2010 and nearly all of the data 
on meningitis were collected between January and June. Given that measures of vaccine uptake 
were universally high11, and large indirect effects are expected12,13, we did not adjust further for 
country level vaccination uptake (coverage) in the campaigns. 
Prior to 2011, all but one country had introduced the Hib conjugate vaccine while no country had 
introduced pneumococcal conjugate vaccine (PCV)14. PCV was in use in the routine immunisation 
schedule by 2015 in Benin (year of introduction 2011), Burkina Faso (2013), Côte d’Ivoire (2014), 
Ghana (2012), Mali (2011), Niger (2014), and Togo (2014) (Table S1). 
Data analysis 
The primary outcome was the incidence rate ratio (IRR) of suspected meningitis cases in districts 
that had and had not been targeted for immunisation with MenAfriVac®. A negative binomial 
regression model was fitted to case counts at a weekly district level, with person years at risk based 
on the reported district population. The overall model adjusted for country a priori, and country-
level IRR were also estimated. In a sensitivity analysis we just considered the cases occurring during 
the meningitis season, i.e. weeks 1-26, from 1st January of each year for all countries.  We also used 
the data on suspected cases by district and week (for weeks 1-52) to measure the number of 
districts reaching the epidemic threshold of 10 per 100,000 during at least one week in a year for 
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both vaccinated and unvaccinated populations and calculated the relative risk.  Incidence rate ratios 
for NmA disease and disease due to other meningococcal serogroups (nonA-Nm) were estimated for 
the laboratory confirmed cases, considering country-level vaccination status in three categories 
(unvaccinated, partially vaccinated and fully vaccinated as described above). As a check, we also 
examined IRR for pathogens other than Neisseria meningitidis, reported in the surveillance bulletins 
as Spn, Hib or ‘Other’. 
Role of the study sponsor 
The sponsor of the study (WHO) supported the collection and curation of surveillance data and WHO 
employees named as authors contributed to study design, data collection, data analysis, data 
interpretation, and writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
Results 
Descriptive epidemiology  
A total of 260,408 suspected meningitis cases were reported from the 9 countries between 2005 and 
2015, with considerable variation by country and year (Table 1). The largest number of cases 
occurred in 2009 corresponding to a major epidemic in Nigeria and Niger, and the second largest 
peak in 2007 due to an epidemic in Burkina Faso.  The proportion of confirmed cases rose to 19% 
(2778/14451) in 2015 from between 3-8% in the period 2005-2010 (Table 2).   
The distribution of individual pathogens from confirmed cases of bacterial meningitis changed over 
the study period (Table 2). NmA was the main cause of meningitis until the roll-out of MenAfriVac® 
began in late 2010, with a peak of 1994 confirmed cases in 2009, when the majority (73%; 
1456/1994) were from Niger. NmW was detected more frequently after 2010 than before, although 
a large epidemic of NmW in Burkina Faso occurred in 2002 before the study period 15. An epidemic 
of NmX was recorded in Niger in 20063 and in 2010, NmX epidemics occurred in northern and central 
regions of Burkina Faso16. In 2015, there was a major epidemic of group C disease in Niger17.  
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Epidemics of group C disease were also observed in some districts in Nigeria from 2013 onwards2, 
but few cases were laboratory confirmed such that the Nigerian group C outbreaks are not well 
represented in Table 2. Spn remained an important cause of meningitis throughout the study period 
and there were relatively few cases of Hib or other pathogens, excepting 2015, when nearly 6870% 
(143of the /210) of the ‘other’ pathogens were reported from Benin (which were incompletely 
characterised as gram stain positive bacteria).  
Impact of MenAfriVac®  
We estimate that the introduction of MenAfriVac® resulted in a 57% (95%CI 55-59%) decline in 
incidence of suspected meningitis cases overall (Table 3). There was a decline of 60% (95%CI 58-
62%) considering just those cases occurring in the meningitis season. The impact of vaccine 
introduction varied by country. Reductions in the incidence of suspected cases were observed after 
vaccination in 7 out of 9 countries from the largest 91% reduction (95%CI 90- 92%) in Chad to 35% 
reduction (95%CI 29-42%) in Niger, where the overall effect of MenAfriVac® on suspected cases was 
moderated by the 2015 group C epidemic. There was an increase in the incidence rate ratio in Benin 
(IRR 4.04, 95%CI 3.56, 4.59) and Ghana (IRR 1.64, 95% CI 1.36, 1.98). Both countries experienced 
fewer than 1200 suspected cases per year, with a mean of 510 (Benin) and 544 (Ghana). The results 
are not driven by a particular district in either country. The more specific data on laboratory 
confirmed cases for these countries do not indicate an increase in any specific pathogen, with very 
few NmA cases after 2010. Excluding Benin and Ghana from the regression model leads to a greater 
impact estimate of 70% reduction in suspected meningitis cases after vaccine introduction (IRR 0.3, 
95% CI 0.29, 0.31).  
Examining the number of districts that reach the epidemic threshold of 10 per 100,000 per week in 
at least one week per year also demonstrates a significant impact of MenAfriVac®. In unvaccinated 
populations, the epidemic threshold was reached in 494/9345 districts compared to only 46/2170 
districts in vaccinated populations, giving a relative risk of 0.41 (95% CI 0.31, 0.56), i.e. the risk of a 
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district reaching the epidemic threshold in at least one week of the year is approximately 60% lower 
in vaccinated compared to unvaccinated populations.  
The number of confirmed NmA cases declined dramatically following the introduction of 
MenAfriVac® (Figure 1). Between 2011 and 2015 only 168 cases of NmA were confirmed overall, 
with only 9 reported in countries that had completed their MenAfriVac® campaigns. There was a 
dramatic decline in confirmed NmA overall, with an incidence rate ratio before and after vaccination 
for NmA of 0.06 (95% CI 0.01, 0.39) for partially vaccinated populations and 0.002 (95% CI 0.000, 
0.009) for “fully vaccinated” populations; i.e. >99% decline in confirmed NmA in countries that have 
completed MenAfriVac® campaigns.  
The number of cases due to N. meningitidis serogroups other than A increased after  MenAfriVac® 
introduction (Figure 1). The incidence rate ratio for non-A Nm serogroups before and after 
vaccination was 2.48 (95% CI 0.68, 9.09) for partially vaccinated and 2.76 (95% CI 1.21, 6.30) for fully 
vaccinated populations. Outbreaks of NmW occurred in Burkina Faso after MenAfriVac® introduction 
in 2012 and there was a large NmC outbreak in Niger & Nigeria in 2015 (Table 2).  However, 
outbreaks due to serogroups other than A were observed before MenAfriVac introduction (Figure 1, 
Table 2). If we remove the largest non-NmA outbreak (Niger, group C, 2015) then the IRR for “fully 
vaccinated” populations reduces to 2.39 (95% CI 0.98, 5.84), where the lower limit of the confidence 
interval is less than 1.  
In terms of other meningitis pathogens, of which the majority are Spn, there was no significant 
change before and after MenAfriVac® introduction over the study period (IRR 0.91 95% CI 0.59, 
1.43). 
 
 9 
 
Discussion 
The introduction of MenAfriVac® into the meningitis belt through mass immunisation campaigns of 
1-29 year olds has had a dramatic impact on the incidence of suspected and confirmed meningitis 
cases. A consistent and substantial reduction was seen on confirmed NmA cases, with only 9 cases 
occurring in countries after the completion of mass campaigns. We estimated that the incidence of 
suspected meningitis cases fell by around 60% in vaccinated compared to unvaccinated populations. 
We found a similar decline in the number of districts reaching the epidemic threshold.  There was an 
increase in the incidence rate ratio of meningococcal serogroups other than A. 
This is the first multi-country study to estimate the impact of MenAfriVac®. It was not possible to 
include all countries in the meningitis belt because not all countries have consistently reported to IST 
over the study period and not all had introduced MenAfriVac® by 2014. In the nine included 
countries, substantial efforts have been made to improve data quality, as evidenced by the 
increasing proportions of suspected cases that are confirmed. Nevertheless, data quality remains a 
concern and poses challenges for the interpretation of the surveillance data. For example, in Benin 
and Ghana, the incidence rate ratio for suspected meningitis cases was higher post-MenAfriVac®. 
Since the number of suspected cases was relatively low and the confirmed case data show no group 
A disease after vaccine introduction and a mix of other pathogens, it is likely that this reflects 
improvements in the sensitivity of surveillance over time rather than a genuine increase in disease. 
Excluding these two countries increased the estimated impact on suspected cases to 70% reduction. 
As we were not able to quantify surveillance quality, this could not be formally included in the 
regression models; the relatively narrow confidence intervals around our incidence rate ratios may 
therefore be somewhat artificial.  Initiatives to further improve surveillance, such as MenAfriNet, 
which supports meningitis case-based surveillance in Burkina Faso, Chad, Mali, Niger and Togo, are 
ongoing. Encouragement is being given to improve surveillance and reporting in the other 17 
countries not included in these analyses but among the total of 26 countries targeted for 
 10 
 
MenAfriVac immunisation. Our analyses accounted for the timing of vaccine introduction at a 
country and district level, but did not include measures of vaccine uptake. This information is often 
not confirmed at district level, and vaccine uptake was reported as exceptionally high11.   
We observed an increase over time in the incidence rate ratio of confirmed cases due to other (non-
A) meningococcal serogroups in vaccinated compared to previously unvaccinated populations. The 
emergence of a novel serogroup C strain causing epidemics in Niger18 and Nigeria2 is a key event, 
and indeed the IRR decreases if the data from the epidemic in Niger in 2015 are removed. The extent 
to which the observed increases in non-A serogroups are an artefact of improved surveillance, a 
reflection of the dynamic nature of meningococcal infection or a phenomenon associated with 
selective vaccine introduction is not clear.  Serotype replacement has been important for 7-and 13-
valent pneumococcal conjugate vaccines19, but replacement with non-vaccine types has not been 
observed for Hib or MenC conjugate vaccines20.  Although MenAfriVac® reduces carriage of 
serogroup A12,13 , carriage of serogroup A across the meningitis belt before vaccine introduction was 
infrequent13,21, as observed with MenC in the UK. This means that any ecological niche in the 
pharynx left by serogroup A is small, which may  offer minimal opportunity for replacement. Another 
possible mechanism for serogroup C to emerge as a direct result of MenAfriVac introduction and 
subsequent selection pressures would be capsule switching from group A to C. However, this does 
not seem to have occurred as  the serogoup C clone in Niger and Nigeria is completely novel, it was 
first isolated in non-vaccinated districts, and there are no known group A strains with the same 
unusual porA (P1.21-15,16) and sequence type (ST-10217) either in disease or carriage isolates. 
Furthermore, Nm assigned to ST-5 clonal complex, especially ST-7 and ST-2859, have not been found 
with a capsule other than A. Given the temporal variability in both incidence and the predominant 
outbreak strains before MenAfriVac® introduction, and further evidence on the dynamic nature of 
meningococcal carriage in Africa21 it seems that the most likely explanation is that these increases 
are due to natural ecological changes. Improvements in reporting and confirmation of cases over 
time may also have contributed to this finding, but we did not have any metrics on surveillance 
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quality to include in our statistical model. Interestingly there was no increase in reporting of 
meningitis due to other pathogens before and after MenAfriVac® introduction  (IRR 0.91 95% CI 
0.59, 1.43), as this in some way serves as a negative control for our studies of primarily 
meningococcal meningitis. (Note that in all countries except Chad, PCV was introduced into the 
routine infant immunisation programme between 2011 and 2015. As the vaccine is given only to 
infants, and the vaccinated cohorts currently make up a small proportion of the population, this is 
unlikely to have had substantial population level effects on pneumococcal meningitis incidence.)  
Given the long term irregular fluctuations in meningitis incidence across the meningitis belt, analysis 
of trends would ideally have included longer periods of analysis before and after vaccine 
introduction. Ongoing, good quality surveillance is essential to fully understand vaccine impact, 
including replacement.  
The success of MenAfriVac® as a model of public-private vaccine development to meet a pressing 
public health need is already assured8. These findings illustrate the health impact of this vaccine. This 
is seen in both the reduction in disease burden as measured in numbers of cases, but also through 
the reduced risk of epidemics on a district level, which are hugely disruptive to general health 
services as well as to communities. It is crucial to build on this success by completing the roll-out of 
mass campaigns and rapidly incorporating MenAfriVac® into routine EPI22. Improving the capacity to 
thoroughly investigate and document any cases of NmA in vaccinated areas is important for ongoing 
monitoring which will enable the post-MenAfriVac® reality to be fully appreciated. This will also 
allow the effects of other vaccines (such as Hib or pneumococcal) on meningitis trends to be further 
documented. There are however, some signs for caution, particularly in the observation of 
epidemics due to other meningococcal serogroups. This further highlights the need for continued 
vigilance and high quality surveillance. The WHO guidelines on epidemic meningitis, which were 
revised in the light of the declining burden of NmA, have implemented a lower alert threshold of 3 
per 100,000 per week (from 5 per 100,000 per week) to improve preparedness and decrease 
response time in the event of an epidemic.  Improvements in clinical care could also reduce the 
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mortality from meningitis23.  In the longer term, there are prospects for multi-valent meningococcal 
conjugate vaccines, which are likely to be a valuable tool for the prevention of meningitis in 
countries at highest risk.  
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Research in context 
Evidence before this study 
We searched PubMed in October 2016 for papers on MenAfriVac® impact using the search terms 
("MenAfriVac" OR "PsA-TT") AND ("disease" OR "carriage") AND ("Africa" OR "meningitis belt") and 
reports submitted to MVP. Publication dates and languages were not limited. Prior to this study, 
evidence that MenAfriVac® was effective against both meningitis and group A carriage had been 
reported from Chad and Burkina Faso. A previous report on surveillance data in 10 countries 
reporting to WHO’s Inter-country support team in Burkina Faso showed a dramatic fall in NmA 
disease after the introduction of MenAfriVac® to 2013 but did not include a robust statistical 
analysis. 
Added value of this study 
This is the first multi-country description and robust statistical analysis of the impact of 
MenAfriVac®. The study provides evidence that the overall burden of suspected meningitis is 
reduced by around 60%, that NmA is confirmed very rarely in vaccinated populations and that 
meningitis caused by other meningococcal serogroups and other pathogens remains a concern.  
Implications of all the available evidence 
Given the observed impact on meningitis, this study supports the continued roll-out of MenAfriVac® 
and incorporation into the routine immunisation schedule of affected countries. Continued efforts to 
strengthen meningitis surveillance and outbreak response in the meningitis belt are required. There 
is a need for multi-valent meningococcal conjugate vaccines to further reduce the burden of 
epidemic meningitis.    
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Legends for figures and tables 
 
Figure 1: Total annual suspected and confirmed cases of bacterial meningitis across all 7 countries in 
relation to MenAfriVac introduction (dotted line). 
 
Table 1: Suspected meningitis cases by year in nine countries of the African meningitis belt, 2005-
2015.  
 
Table 2: Confirmed Meningitis Cases and Organisms isolated from CSF in nine countries of the African 
Meningitis Belt, 2005–2015 
 
Table 3: Impact of MenAfriVac® on suspected cases of meningitis reported by district and week. 
Incidence rate ratios (IRR) comparing vaccinated to unvaccinated time periods. 
 
Figure S1: Annual incidence of suspected and confirmed cases of bacterial meningitis per 100,000 by 
country. Year of MenAfriVac introduction indicated by dotted line. 
 
Figure S2: Annual incidence of confirmed cases of group A meningococcal, non-A meningococcal, and 
other bacterial meningitis per 100,000 by country. Year of MenAfriVac introduction indicated by 
dotted line. 
 
Table S1: Timing of vaccine introduction for MenAfriVac® (campaigns of 1-29 year olds), routine 
infant pneumococcal conjugate vaccine (PCV), and routine infant Hib conjugate vaccine by country. 
